Published in Vaccine Weekly, November 9th, 2005
Under the agreement HID is required to order and pay for minimum annual quantities of Sci-B-VacTM, either as dispensed doses or bulk antigen, for 7 years. In the former case, the minimum allocation of final product per annum will generate revenues of USD $210 million for SciGen over 7 years. For bulk antigen, the 7-year order would total USD $145 million.
HID has been appointed as the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.